Amneal Pharmaceuticals, Inc. (AMRX)
NASDAQ: AMRX · IEX Real-Time Price · USD
6.54
+0.12 (1.87%)
At close: Jul 2, 2024, 4:00 PM
6.68
+0.14 (2.14%)
After-hours: Jul 2, 2024, 7:57 PM EDT
Amneal Pharmaceuticals Revenue
Amneal Pharmaceuticals had revenue of $2.50B in the twelve months ending March 31, 2024, with 9.82% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $659.19M with 18.23% year-over-year growth. In the year 2023, Amneal Pharmaceuticals had annual revenue of $2.39B with 8.20% growth.
Revenue (ttm)
$2.50B
Revenue Growth
+9.82%
P/S Ratio
0.81
Revenue / Employee
$324,059
Employees
7,700
Market Cap
2.02B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2.39B | 181.30M | 8.20% |
Dec 31, 2022 | 2.21B | 118.64M | 5.67% |
Dec 31, 2021 | 2.09B | 101.15M | 5.08% |
Dec 31, 2020 | 1.99B | 366.15M | 22.51% |
Dec 31, 2019 | 1.63B | -36.62M | -2.20% |
Dec 31, 2018 | 1.66B | 629.34M | 60.88% |
Dec 31, 2017 | 1.03B | 15.43M | 1.52% |
Dec 31, 2016 | 1.02B | 151.95M | 17.54% |
Dec 31, 2015 | 866.28M | 80.66M | 10.27% |
Dec 31, 2014 | 785.62M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BrightSpring Health Services | 9.37B |
AMN Healthcare Services | 3.48B |
Privia Health Group | 1.69B |
Astrana Health | 1.45B |
Premier | 1.34B |
Amphastar Pharmaceuticals | 676.21M |
UFP Technologies | 407.33M |
Protagonist Therapeutics | 314.95M |
AMRX News
- 1 day ago - Amneal Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar - Business Wire
- 1 day ago - Kashiv BioSciences Enters into Exclusive Licensing Agreement with Amneal for Commercialization of a Proposed Biosimilar to XOLAIR® (Omalizumab) - Business Wire
- 4 days ago - Amneal Releases 2023 Environmental, Social and Governance Report - Business Wire
- 27 days ago - Amneal Expands Broad Injectables Portfolio to Over 40 Products with the Addition of Six New Therapies - Business Wire
- 5 weeks ago - Amneal Begins Supplying Over-the-Counter Naloxone Hydrochloride Nasal Spray to U.S. Retail Pharmacies and the State of California - Business Wire
- 5 weeks ago - Amneal to Participate at Upcoming Investor Conference - Business Wire
- 2 months ago - Drugmaker Amneal agrees to $270 million U.S. opioid settlement - Reuters
- 2 months ago - Amneal Reports First Quarter 2024 Financial Results - Business Wire